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METHODS: Computer simulations were done to illus-
trate scenarios where statistical modeling would ﬁnd 
differences between antibiotics with identical MIC50,
MIC90 and % SUS. The Base2 logarithm of AB dilution
was substituted for time in KM analyses. The KM analy-
ses detected differences in AB activity (P < 0.00005 to
0.0281) because KM compares across the entire range of
dilutions instead of only at single points like MIC50 and
MIC90. After developing the application with computer
simulation the method was tested by comparing MIC
data for piperacillin/tazobactam (PT) versus ticarcillin/
clavulanate (TC) against Klebsiella pneumoniae (4,784
isolates) and Morganella morganii (719 isolates) from a
previous study (ICAAC abstract A-57, 1996).
RESULTS: In spite of identical MIC90 and % SUS using
NCCLS criteria the MM of survival using KM analyses
showed TC superior against Klebsiella pneumoniae and
PT superior against Morganella morganii (both P <
0.00005).
CONCLUSION: Application of this Mathematical
Model and Kaplin Meier survival table analyses can dis-
cover differences in antibiotic activity hidden from tradi-
tional methods and may improve the clinical utility of in
vitro data.
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As with many economic concepts, costs are context-
speciﬁc, and are estimated to reﬂect the nature of the
problem being addressed and the perspective of the deci-
sion-maker. Four concepts are considered when estimat-
ing costs: scope, scale, perspective and measurement
approach.
OBJECTIVE: The main objective is to assess the use and
appropriateness of different costing methods and discuss
issues surrounding the selection and construction of costs.
A cost-effectiveness analysis was performed to evaluate
the possible introduction of the pneumococcal conjugate
vaccine into vaccination programmes and is used as the
example.
METHODS: Resource use and unit cost data were col-
lected in Brazil, Chile and Uruguay separately to enable
country-speciﬁc analysis of the data. Items of health care
resource were deﬁned a priori in standardised forms. The
perspectives of the costing was the health care system 
and society. The price paid and social opportunity cost
approaches were used for unit cost estimations. Unit costs
for resource items were drawn from observational studies
or constructed from detailed costing exercises in speciﬁc
institutions.
RESULTS: Data availability between countries was vari-
able. In some cases costs could not be obtained due to
inter-country variations in clinical practice. Differences in
the organisation and delivery of care and reimbursement
of health care providers increased the variability of data
quantity and quality between countries. For some items
it proved necessary to use hospital charges as a proxy for
hospital costs. Several problems arose when estimating
hospital ward costs. Some available data sets gave a ﬁgure
for hotel costs excluding any medical costs. In the may-
ority of cases, however, it was not clear what was
included in the ward costs, which varied between 
hospitals.
CONCLUSION: It is possible to use various costing
methods in multi-national economic evaluations as long
as methods are standardised.
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Commonly, research to assess the value of medication
therapy in schizophrenia includes the assumption that the
most effective antipsychotic agent will invariably lead to
a reduction in medical services, thereby reducing total
direct costs within a system of care.
OBJECTIVES: In this methods paper, we argue that
quantifying decreases in certain medical costs (i.e., acute
care) associated with medication treatment can be key in
decisions to purchase, prescribe, or reimburse. We also
propose that pharmacoeconomic researchers consider the
complexities of interpreting outpatient service use for
those with schizophrenia.
METHODS: We discuss the notion that increased use of
certain services may indicate that individuals are respond-
ing to medication, are engaged in their treatment plans,
and are tending to previously-neglected routine health
care needs. Additionally, we provide evidence that short-
term increases in outpatient service use may be highly
consistent with published standards for comprehensive
maintenance treatment of schizophrenia.
RESULTS: We present data illustrating the importance of
disaggregating service types when attempting to under-
stand the relationship between treatment response and
costs. Analyses should also include both a short-term 
and a longer-term perspective, to determine the extent to
which an initial “investment” in medication and perhaps
other (outpatient) treatment is likely to “pay off” through
reductions in subsequent ER and hospitalization costs,
and in individuals more able to lead productive and
enjoyable lives.
CONCLUSIONS: Research and policy focused solely on
decreases in total costs (i.e., fewer services received) can
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underestimate the complexity of both treatment and out-
comes for those with schizophrenia.
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OBJECTIVE: Medical records provide a potential wealth
of information about treatment effects; however, differ-
ences in pretreatment patient or other characteristics may
inﬂuence treatment assignment. This, in turn, could lead
to biased estimates of treatment effects in nonrandomized
studies. We developed a statistical model using propen-
sity scores to reduce treatment selection bias in analyses
based on retrospective data.
METHODS: As part of a study described elsewhere, we
abstracted retrospective data from the medical records of
327 patients treated for schizophrenia or schizoaffective
disorder with risperidone, olanzapine, or quetiapine at 
3 acute inpatient mental health facilities. Data were 
collected on patients from the inpatient hospitalization
through 60 days following initiation of study drug. Using
a multinomial logistic regression analysis of pretreatment
patient and other characteristics, we developed a predic-
tive model of treatment assignment to risperidone, 
olanzapine, or quetiapine.
RESULTS: The following variables were signiﬁcantly pre-
dictive of treatment assignment: age at admission, gender,
race, smoker at admission, history of substance abuse,
prior use of clozapine, and facility. The following vari-
ables were among those not signiﬁcantly predictive of
treatment assignment: prior use of atypical antipsychotics
other than clozapine, body mass index at admission, 
age at ﬁrst hospitalization for mental illness, and history
of suicide attempts, violence, glucose abnormalities, or
seizures.
CONCLUSION: The propensity score model offered a
means to adjust for treatment selection bias in a nonran-
domized study comparing treatment effects of risperi-
done, olanzapine, and quetiapine in an inpatient setting.
In addition, the propensity score methodology can be
used by researchers responsible for designing non-
randomized studies of healthcare interventions and 
decision-makers who are responsible for evaluating and
interpreting the results in this disease area.
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OBJECTIVES: Although effective pharmacologic treat-
ment for attention-deﬁcit/hyperactivity disorder (ADHD)
is widely available, little is know about the quality of such
care. This is unfortunate, because the burden of inappro-
priate or inadequate treatment, in terms of increased risk
for psychiatric comorbidity, chronic decrements in func-
tioning, and higher medical costs, is borne by patients,
families, employers and healthcare systems. We therefore
sought to develop a methodology to evaluate quality of
ADHD pharmacologic care.
METHODS: Among members continuously enrolled in a
pharmacy beneﬁts management plan during the year
2000, we used claims data to identify all psychostimu-
lants ﬁlled for ADHD-related treatment during a 3-month
index period (108, 819 ﬁlls for 51, 486 patients). We next
calculated average daily dose by psychostimulant class
(methylphenidate, amphetamine salts, dextroampheta-
mine, pemoline, and methamphetamine). Based upon 
previous research, we then created a metric to convert
average daily dose across psychostimulant classes into
“Methylphenidate Equivalent Units” (MEU).
RESULTS: Average daily MEU dose was 27.3mg.
Patients averaged 2.1 ﬁlls per 3-month period, at an
average of 25.5 days supplied per ﬁll. Thus, patients typ-
ically received medication coverage throughout 51 of 
the 91-day index period (56%). This is the equivalent of
receiving medication coverage for 3.9 days per week. If
medication was, in fact, taken every day, average daily
MEU dose would be nearly halved (15.3mg).
CONCLUSIONS: We describe a methodology for evalu-
ating quality of ADHD pharmacologic care. Whether
ﬁndings suggest under-treatment requires future research
linking average daily MEU dose to targeted outcomes 
of care. Guidelines recently published by the American
Academy of Pediatrics note that ADHD treatment
requires continuous monitoring “to maximize function
across multiple domains.” By incorporating our method-
ology into large-scale prescription feedback and moni-
toring systems, the burden of inappropriate or inadequate
ADHD treatment that is borne by patients, families,
employers, and healthcare systems may be ultimately 
mitigated.
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